15:59 , Nov 16, 2018 |  BC Week In Review  |  Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

United Therapeutics Corp. (NASDAQ:UTHR) licensed exclusive, worldwide rights to pulmonary arterial hypertension compound ralinepag from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) in a Nov. 15 deal that highlights how far Arena’s come since it shifted its focus...
00:26 , Nov 16, 2018 |  BC Extra  |  Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

United Therapeutics Corp. (NASDAQ:UTHR) licensed exclusive, worldwide rights to pulmonary arterial hypertension compound ralinepag from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) on Thursday in a deal that highlights how far Arena’s come since it shifted its focus...
18:56 , Jul 13, 2018 |  BC Week In Review  |  Financial News

Idorsia raises $511.9M in dual offerings

Idorsia Ltd. (SIX:IDIA) raised on July 11 CHF505.2 million ($511.9 million) in a pair of private placements underwritten by Credit Suisse, Goldman Sachs and Octavian. Idorsia raised CHF305.2 million ($309.2 million) through the sale of...
18:36 , Jul 12, 2018 |  BC Extra  |  Financial News

Idorsia raises $511.9M in dual offerings

Idorsia Ltd. (SIX:IDIA) raised CHF505.2 million ($511.9 million) in a pair of private placements underwritten by Credit Suisse, Goldman Sachs and Octavian. Idorsia raised CHF305.2 million ($309.2 million) through the sale of 11.9 million shares...
19:32 , Jun 15, 2018 |  BC Week In Review  |  Financial News

Autolus proposes IPO terms

Cell therapy developer Autolus Therapeutics Ltd. (London, U.K.) revealed terms for its proposed IPO on NASDAQ. In a regulatory filing June 8, the company proposed to sell 7.8 million ADSs at $15-$17, with each ADS...
13:09 , Jun 8, 2018 |  BC Extra  |  Financial News

Autolus proposes IPO terms

Cell therapy developer Autolus Therapeutics Ltd. (London, U.K.) revealed terms for its proposed IPO on NASDAQ. In a regulatory filing Friday, the company proposed to sell 7.8 million ADSs at $15-$17, with each ADS representing...
22:48 , May 31, 2018 |  BC Extra  |  Politics & Policy

FDA unveils guidance aimed at curbing REMS abuse

FDA released new guidance documents Thursday that are intended to curtail the abuse of REMS to stall generic competition. The guidances clarify the requirements for REMS when they are to be shared by both branded...
21:15 , May 18, 2018 |  BioCentury  |  Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of...
19:08 , May 18, 2018 |  BC Week In Review  |  Company News

FDA names, shames ‘anticompetitive’ drug companies

FDA Commissioner Scott Gottlieb Thursday made public a list of 41 branded drug companies that generics manufacturers have accused of blocking access to drug samples to thwart development of competitive generic drugs. The list includes...
19:34 , May 17, 2018 |  BC Innovations  |  Finance

Europe’s piece of the pie

With China’s rising infrastructure for life science innovation and the unabated growth of U.S. science, Europe has two cards to play that can help it compete globally: expertise in key core technologies and its centralized...